用卡博赞提尼布治疗肝细胞癌的成功的二线治疗,该癌症含有细胞质介质细胞-上皮细胞过渡因子放大
Makoto Yamamoto1, Takeshi Terashima1, Tatsuya Yamashita1
1Department of Gastroenterology, Kanazawa University Hospital, Kanazawa, Ishikawa, Japan.
概括
综合的基因组分析确定了一名患有转移性肝细胞癌的患者的MET放大,该患者的肝细胞癌在阿特佐利祖马布和贝瓦西祖马布的治疗中进展. 卡博桑提尼布治疗导致了显著的瘤缩,突出显示了剖析.
科学领域:
- 在瘤学瘤学.
- 基因组学就是基因组学.
- 医疗治疗 医疗治疗
背景情况:
- 肝细胞癌 (HCC) 是一种主要的肝癌,治疗选择有限.
- 晚期HCC的第一线治疗通常涉及免疫疗法组合,如阿特佐利祖马布加贝瓦西祖马布.
- 在一线治疗后疾病的进展需要有效的二线治疗策略.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.3K
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
8.9K
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
